Advertisement

Type 2 Diabetes

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA Alert
shutterstock
FDA Alert
FDA Approves Semaglutide For Reducing Serious Cardiovascular Events Among Adults With Heart Disease and Obesity, Overweight
03/21/2024

Anthony Calabro, MA

Anthony Calabro, MA
On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...
03/21/2024
FDA Alert
fda
FDA Alert
Tirzepatide Gains FDA Approval for Chronic Weight Management
11/13/2023
Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.
11/13/2023
FDA Alert
FDA Alert
FDA Alert
FDA Approves Two Medications to Treat Pediatric Patients With Type 2 Diabetes
08/10/2023

Jessica Ganga

Jessica Ganga
The FDA has approved empagliflozin, and empagliflozin and hydrochloride to help manage type 2 diabetes in pediatric patients.
08/10/2023
treatment
treatment
FDA Approves New Treatment for T2D
05/16/2022
A new treatment option for the management of blood sugar in individuals with type 2 diabetes is approved under FDA priority review designation.
05/16/2022